GlassScriptPhysician profile
Hashim R Kazmi
NPI 1538270038
$99,019.89
in general payments reported to CMS, 2019-2025
28 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $7,747 · 2021: $15K · 2022: $36K · 2023: $20K · 2024: $1,030 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,258 · Honoraria: $4,000 · Travel and Lodging: $2,477 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,704.00 |
| Food and Beverage | $4,257.57 |
| Honoraria | $4,000.00 |
| Travel and Lodging | $2,476.71 |
| Education | $107.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $40,554.55 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $32,589.56 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $15,922.88 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $5,506.35 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $756.31 | 2021-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $629.19 | 2022-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $588.52 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Ardelyx, INC. | $357.02 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Ani Pharmaceuticals, INC. | $296.99 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $270.17 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $255.05 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $196.12 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $172.69 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $169.50 | 2019-2025 | Jynarque |
| Daiichi Sankyo INC. | $135.49 | 2019-2023 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $112.08 | 2019-2020 | |
| Genzyme Corporation | $102.43 | 2023 | |
| Mallinckrodt Enterprises LLC | $64.81 | 2019 | |
| Outset Medical INC | $60.75 | 2024 | |
| Akebia Therapeutics INC | $56.62 | 2019-2025 | Vafseo |
| Kyowa Kirin, INC. | $55.92 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2024-2025 | Jardiance |
| Baxter Healthcare | $25.42 | 2019 | |
| Novo Nordisk INC | $25.15 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.12 | 2022 | |
| Lilly USA, LLC | $20.82 | 2024 | Jardiance |
| Pfizer INC. | $17.93 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashim Kazmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.